{
    "nct_id": "NCT04535141",
    "official_title": "Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant",
    "inclusion_criteria": "1. Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information.\n2. Recipients receiving autologous or allogeneic HCT for any disease\n3. Any conditioning chemotherapy regimen considered a standard bone marrow transplantation conditioning regimen\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n5. The subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients must not have started conditioning chemotherapy prior to consent. Note: test dose Busulfan is not part of conditioning chemotherapy\n2. Known allergy to olanzapine\n3. Baseline corrected QT interval ( QTc )>500 msec as calculated by the Fridericia formula\n4. Patients receiving post-transplant cyclophosphamide as planned graft-versus-host disease (GVHD) prophylaxis\n5. Pregnant or breastfeeding (NOTE: patients pregnant or breast-feeding are not eligible to proceed to transplant).\n6. Has a known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least five years.\n7. Treatment with any investigational drug within 7 days prior to registration.\n8. Subject is receiving prohibited medications (ciprofloxacin or fluvoxamine) that cannot be discontinued/replaced by an alternative therapy.",
    "miscellaneous_criteria": ""
}